Emily Field
Stock Analyst at Barclays
(1.70)
# 3,406
Out of 5,147 analysts
15
Total ratings
75%
Success rate
-0.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Field
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Initiates: Underweight | $25 | $27.65 | -9.58% | 1 | Feb 20, 2026 | |
| MRK Merck & Co. | Initiates: Overweight | $140 | $123.82 | +13.07% | 1 | Feb 20, 2026 | |
| GILD Gilead Sciences | Initiates: Equal-Weight | $155 | $148.95 | +4.06% | 1 | Feb 20, 2026 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $1,350 | $1,051.99 | +28.33% | 1 | Feb 20, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $75 | $62.37 | +20.25% | 1 | Feb 20, 2026 | |
| BIIB Biogen | Initiates: Equal-Weight | $185 | $191.82 | -3.56% | 1 | Feb 20, 2026 | |
| AMGN Amgen | Initiates: Equal-Weight | $350 | $388.16 | -9.83% | 1 | Feb 20, 2026 | |
| ABBV AbbVie | Initiates: Overweight | $275 | $232.08 | +18.49% | 1 | Feb 20, 2026 | |
| NVO Novo Nordisk | Downgrades: Equal-Weight | n/a | $37.45 | - | 1 | Jul 30, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | n/a | $33.66 | - | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | n/a | $59.13 | - | 4 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $766.92 | - | 1 | Oct 19, 2021 |
Pfizer
Feb 20, 2026
Initiates: Underweight
Price Target: $25
Current: $27.65
Upside: -9.58%
Merck & Co.
Feb 20, 2026
Initiates: Overweight
Price Target: $140
Current: $123.82
Upside: +13.07%
Gilead Sciences
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $155
Current: $148.95
Upside: +4.06%
Eli Lilly and Company
Feb 20, 2026
Initiates: Overweight
Price Target: $1,350
Current: $1,051.99
Upside: +28.33%
Bristol-Myers Squibb Company
Feb 20, 2026
Initiates: Overweight
Price Target: $75
Current: $62.37
Upside: +20.25%
Biogen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $185
Current: $191.82
Upside: -3.56%
Amgen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $350
Current: $388.16
Upside: -9.83%
AbbVie
Feb 20, 2026
Initiates: Overweight
Price Target: $275
Current: $232.08
Upside: +18.49%
Novo Nordisk
Jul 30, 2025
Downgrades: Equal-Weight
Price Target: n/a
Current: $37.45
Upside: -
Galapagos NV
Jan 23, 2025
Downgrades: Underweight
Price Target: n/a
Current: $33.66
Upside: -
Nov 5, 2021
Upgrades: Equal-Weight
Price Target: n/a
Current: $59.13
Upside: -
Oct 19, 2021
Upgrades: Overweight
Price Target: n/a
Current: $766.92
Upside: -